Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study

Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age3-12
SponsorAdia Med of Winter Park LLC

About this trial

This 24-month study is testing whether adding AdiaVita, an umbilical cord blood-derived stem cell and exosome product, to glutathione therapy helps improve autism symptoms in children ages 3-12 more than glutathione alone. Children will be randomly placed into one of two groups for the first three months: one group receives glutathione only, and the other receives glutathione plus monthly intravenous AdiaVita infusions. Both groups also use topical glutathione cream twice daily at home. Autism symptoms will be tracked over two years using the Autism Treatment Evaluation Checklist (ATEC) filled out by parents and by therapists or teachers. Safety, side effects, quality of life, and overall well-being will be closely monitored through regular clinic visits, physical exams, blood tests, and adverse event reporting. After the initial three-month phase, children who received glutathione alone may cross over to receive AdiaVita infusions at no additional cost if safety checks at month 6 are satisfactory. Approximately 100 children with a confirmed autism diagnosis from the Central Florida area will take part. Participation is completely voluntary, and families may withdraw at any time.

Eligibility criteria

Qualifiers

Age 3-12 years

Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2)

Parent/guardian willingness to consider experimental treatments and comply with study requirements

Ability to attend all scheduled visits

Disqualifiers

Severe allergies to study products

Significant uncontrolled medical conditions

Pregnancy or breastfeeding (if applicable)

Participation in another interventional trial within 30 days

Trial design

Treatments tested in this trial

  • Umbilical Cord Blood-Derived Stem Cells and Exosomes
  • Glutathione

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators